Feb 10, 2009 - OSI Pharmaceuticals, Inc. announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application to the U.S. FDA requesting permission to manufacture and market a generic version of Tarceva (erlotinib).
The details can be read here.
No comments:
Post a Comment